WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100190
CAS#: 6055-19-2 (hydrate)
Description: Cyclophosphamide, also known as cytophosphane among other, is used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. As an immune suppressor it is used in nephrotic syndrome and following organ transplant. It is taken by mouth or injection into a vein. The main effect of cyclophosphamide is due to its metabolite phosphoramide mustard. This metabolite is only formed in cells that have low levels of ALDH. Phosphoramide mustard forms DNA crosslinks both between and within DNA strands at guanine N-7 positions (known as interstrand and intrastrand crosslinkages, respectively). This is irreversible and leads to cell apoptosis.
MedKoo Cat#: 100190
Name: Cyclophosphamide monohydrate
CAS#: 6055-19-2 (hydrate)
Chemical Formula: C7H15Cl2N2O2P
Molecular Weight: 279.10124
Elemental Analysis: C, 32.20; H, 5.79; Cl, 27.16; N, 10.73; O, 12.26; P, 11.86
Cyclophosphamide Monohydrate, purity > 98%, is in stock.
Synonym: Ciclofosfamida; Ciclofosfamide; Cyclophosphamide monohydrate.
IUPAC/Chemical Name: 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
InChi Key: PWOQRKCAHTVFLB-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2
SMILES Code: ClCCN(P1(OCCCN1)=O)CCCl.[H]O[H]
The following data is based on the product molecular weight 279.10124 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: RodrÃguez PC, RodrÃguez G, GonzÃ¡lez G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010 Winter;12(1):17-23. Review. PubMed PMID: 20387330.
2: Teicher BA. In vivo/ex vivo and in situ assays used in cancer research: a brief review. Toxicol Pathol. 2009;37(1):114-22. Epub 2008 Dec 19. Review. PubMed PMID: 19098118.
3: Ballatori E, Roila F, Ruggeri B, De Angelis V, Porzio G, Marchetti P; Italian Group for Antiemetic Research. Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials. Tumori. 2007 Nov-Dec;93(6):540-3. PubMed PMID: 18338486.
4: Chen CS, Jounaidi Y, Su T, Waxman DJ. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14. PubMed PMID: 17853921; PubMed Central PMCID: PMC2613860.
5: Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. Review. PubMed PMID: 17430192.
6: Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007 Jan 15;67(2):792-801. PubMed PMID: 17234791.
7: Miki T, Mizutani Y, Akaza H, Ozono S, Tsukamoto T, Terachi T, Naito K, Nonomura N, Hara I, Yoshida O; Japan Blood Cell Transplantation Study Group for Testicular Germ Cell Tumor. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor. Int J Urol. 2007 Jan;14(1):54-9. PubMed PMID: 17199861.
8: Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep;24(5):528-34. Review. PubMed PMID: 16939963.
9: Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet. 2006;45(9):871-903. Review. PubMed PMID: 16928151.
10: Zhang J, Tian Q, Zhu YZ, Xu AL, Zhou SF. Reversal of resistance to oxazaphosphorines. Curr Cancer Drug Targets. 2006 Aug;6(5):385-407. Review. PubMed PMID: 16918308.
6055-19-2 (Cyclophosphamide hydrate);
50-18-0 (Cyclophosphamide anhydrous)